Thermo Fisher Scientific Inc. (TMO) · Oct 21, 2026 · Earnings
Beat — Adjusted EPS $6.68 vs ~$6.40 consensus; revenue $12.14B vs ~$11.95B
Thermo Fisher’s Q3 earnings beat consensus on adjusted EPS and revenue, with organic growth improving and margins expanding despite heavier restructuring costs.
Thermo Fisher is a diversified life-science tools, diagnostics, laboratory-supply and biopharma-services provider trying to convert recovering customer activity into durable organic growth, while expanding its role in proteomics, AI-enabled laboratories and precision medicine. Its 2026 strategy has emphasized innovation, customer partnerships and disciplined execution across improving end markets.
The quarter cleared expectations on both major scorecard items. Published Q3 expectations were roughly $6.40 of adjusted EPS and $11.95 billion of revenue; Thermo Fisher delivered $6.68 and $12.137 billion, respectively.
| Metric | Q3 2026 | Q3 2025 | External expectation |
|---|---|---|---|
| Revenue | $12.137B | $11.122B | ~$11.95B |
| Organic revenue growth | 6% | — | — |
| Adjusted EPS | $6.68 〔0〕 | $5.79 | ~$6.40 |
| Adjusted operating margin | 24.5% 〔1〕 | 23.3% | — |
| Free cash flow | $2.115B | $1.840B | — |
The more important operational signal is the acceleration in underlying demand. Reported revenue rose 9%, but acquisitions and divestitures contributed 3 percentage points, leaving 6% organic growth. That is a cleaner improvement in the core business than the headline growth rate suggests, and it supports the prior narrative that customer activity is recovering rather than growth being driven only by acquired assets. The strongest segment momentum came from Laboratory Products and Biopharma Services, where quarterly revenue increased to $6.863 billion from $5.970 billion and segment margin rose to 15.5% from 14.5% (Business Segment Information).
Margin expansion made the beat higher quality. Adjusted operating margin expanded 120 basis points year over year to 24.5%, while Analytical Instruments margin rose to 26.9% from 22.6% and Specialty Diagnostics margin rose to 31.0% from 27.4% (Business Segment Information). That indicates the quarter was not simply a volume win; execution and mix also converted growth into faster operating-profit growth. The offset is that GAAP restructuring and other costs rose to $199 million from $135 million, including a $244 million held-for-sale loss partially offset by a $72 million business-sale gain (Supplemental Information Regarding Non-GAAP Financial Measures).
Cash generation remained supportive, but capital deployment is still aggressive. Nine-month free cash flow reached $4.618 billion versus $3.319 billion a year earlier, yet Thermo Fisher also spent $8.877 billion on acquisitions, issued $5.238 billion of net debt and ended the period with $39.108 billion of long-term obligations (Cash Flow statement; Balance Sheet). That reinforces the company’s acquisitive growth model, while leaving integration and leverage as the main execution constraints rather than immediate operating weakness.
Bottom line: This is a genuine earnings beat, not merely favorable presentation: Thermo Fisher exceeded consensus on EPS and revenue while organic growth and margins improved. The event advances the recovery-and-execution story, although acquisition-heavy capital deployment remains part of the business’s ongoing complexity.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!